Qiagen N : gives drug research direct access to world-leading data with launch of Biomedical Knowledge Base

• Biomedical relationships knowledge will boost applications in drug discovery for data scientists
• Manually curated information on biomedical relationships, complete with causality and context
• Researchers gain flexible access to high-quality data for mining and integration with their processes

Redwood City, California, and Hilden, Germany, April 25, 2022 - QIAGEN Digital Insights, the bioinformatics business of QIAGEN, today announced the launch of QIAGEN Biomedical Knowledge Base in North America, Europe, Japan and Australia to support data science applications in pharmaceuticals and biotechnology that are becoming ever more important for drug discovery.

QIAGEN Biomedical Knowledge Base opens a new industry segment for QIAGEN, targeting data scientists. It enables them to quickly and efficiently access biomedical relationships knowledge from thousands of publications and dozens of databases that can form the foundation for novel, high-quality drug discoveries. This new product adds to QIAGEN's knowledge and database portfolio, which includes troves of information about gene variants and integrated 'omics data.

QIAGEN Biomedical Knowledge Base provides direct access to the same manually curated data that fuels the widely used QIAGEN Ingenuity Pathway Analysis (IPA) application. This knowledge base structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs, chemicals and other objects. It enables biomedical knowledge graph analysis, artificial intelligence, machine learning and other drug discovery applications driven by data science.

"There's no other source of biomedical relationships knowledge as expertly curated or as extensive and granular in content," said Dr. Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. "For over 20 years, we have been assembling this world-leading knowledge base. Previously, it was solely accessible through our industry-leading application, QIAGEN IPA. We are now unlocking our biomedical relationships knowledge to give researchers in pharma and biotech direct access to it."

QIAGEN Biomedical Knowledge Base collects, structures and integrates knowledge about biomedical relationships locked in thousands of publications and dozens of databases, simplifying and accelerating a task that was traditionally extremely arduous and slow. With direct access to QIAGEN's biomedical relationships knowledge, researchers can now focus on answering their scientific questions - instead of spending their valuable time gathering, structuring and cleaning up data.

The launch of QIAGEN Biomedical Knowledge Base gives scientists a powerful tool to accelerate research on disease mechanisms, disease subtypes, target and biomarker identification, mechanisms of action and more. The data is in a format and structure that makes it easy to integrate into data science projects. It creates new opportunities for data scientists within pharma and biotech by providing the flexibility and granularity they require to extract profound insights into their biological questions.

To learn more about QIAGEN Digital Insights knowledge content, databases and related services and products, visit https://digitalinsights.qiagen.com/knowledge-and-databases/.

About QIAGEN Digital Insights

QIAGEN Digital Insights, the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. We have over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 2.5 million profiled patient cases and over 40 billion scientific data points. Discover our portfolio of expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights. Learn more at https://digitalinsights.qiagen.com/.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2021, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).